Periodic Reporting for period 1 - hmqPro (Highly multiplexed, quantitative protein biomarker profiling (hmqPro))
Reporting period: 2022-07-01 to 2023-12-31
The project will develop a multipurpose, highly multiplexed, quantitative protein profiling (hmqPro) platform that can be adapted to a wide range of applications, particularly biomarker discovery. Biomarkers are a 43 Billion USD market spanning applications in diagnostics, drug discovery & development, personalized medicine, disease risk assessment. The project aimed to develop a new quantitative protein profiling platform without the need for specialized laboratory equipment that will have the capacity to impact the biomarker discovery market by combining unique flexibility with high-throughput.
In an academic-commercial partnership between Karolinska Institutet and Epigenica AB, technological foundations were laid for a method comprising antibody-based quantitation of multiple proteins in a large number of samples. Various chemistries and molecular biology steps in the procedure required extensive optimization and trouble-shooting. Alternative quantitation strategies on solid support and in solution were piloted. The outcome of the project is a optimized reagents design and workflow that we will further develop into the intended highly multiplexed protein profiling method in the future.
In parallel with validating the fundamentals of the intended assay platform, we have performed market analysis focussing specifically on diagnostic applications of protein profiling methods in liquid biopsies.
Following up on the results and insights gained in this project, we will continue the product development trajectory, first completing development of the assay platform, then performing a variety of validations on different biological source material and protein targets. Ultimately, the novel hmqPRO assay platform will join Epigenica AB's product development program in form of kit and service offerings.
Following up on the results and insights gained in this project, we will continue the product development trajectory, first completing development of the assay platform, then performing a variety of validations on different biological source material and protein targets. Ultimately, the novel hmqPRO assay platform will join Epigenica AB's product development program in form of kit and service offerings.